Floatz logo

Tsc-204-A0201

Verrucous Carcinoma

TScan Therapeutics, Inc.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Verrucous Carcinoma cohort.

Asset / SponsorPhaseRating
Tsc-204-C0702
TScan Therapeutics, Inc.
Phase 1CC
Tsc-203-A0201
TScan Therapeutics, Inc.
Phase 1CC
Tsc-201-B0702
TScan Therapeutics, Inc.
Phase 1CC
Tsc-204-A0101
TScan Therapeutics, Inc.
Phase 1CC
Tsc-200-A0201
TScan Therapeutics, Inc.
Phase 1CC
Tsc-202-A0201
TScan Therapeutics, Inc.
Phase 1CC

Same molecule, other indications

Tsc-204-A0201 is also rated in:

anogenital human papillomavirus infectionActive
CC
Indicative · Phase 1
43 / 100
View asset →
non-small cell lung carcinomaActive
CC
Indicative · Phase 1
43 / 100
View asset →
cervical carcinomaActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →